Share on LinkedInShare on LinkedIn

ARTICLE · 02 APRIL 2021

Market Intelligence Thought Leadership Award Winner

Takeaways From The Competition Bureau's Participation In The International Working Group Focused On Pharmaceutical Mergers

Canada's Competition Bureau (the "Bureau") has joined an international multilateral working group that will be focusing on the analysis of pharmaceutical mergers.

CanadaAntitrust/Competition Law

Canada's Competition Bureau (the "Bureau") has joined an international multilateral working group that will be focusing on the analysis of pharmaceutical mergers. Initiated by the U.S. Federal Trade Commission, the working group also includes the Antitrust Division of the U.S. Department of Justice, Offices of State Attorneys General, the U.K. Competition and Markets Authority ("CMA") and the European Commission Directorate General for Competition ("European Commission"). According to the Bureau, "(t)he goal of the initiative is to identify concrete steps to review and update the analysis of pharmaceutical mergers, which are often subject to review in multiple jurisdictions." The organizer of the international working group, Acting FTC Chair Rebecca Slaughter, used stronger language, noting that "amid skyrocketing drug prices and ongoing concerns about anticompetitive conduct in the industry, it is imperative that we rethink our approach toward pharmaceutical merger

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from